As gene transfer vehicles, lentiviruses exhibit many desirable properties, such as high transduction efficiencies, ability to infect both dividing and nondividing cells, and stable integration into the host cell genome. However, cost-effective manufacturing of lentiviral vectors at commercial scales has proven difficult and remains a pressing issue for the marketing of therapies that depend on their application.
The viral vector market is highly active, and the interest in production technologies is driven by recent approvals in cell and gene therapy. Here, insights around the challenges in viral vector manufacturing are shared so that a scalable and cost-efficient process suitable for GMP manufacturing environments can be obtained.
Streamlining, connecting, and automating workflows to shape the future of cellular treatment delivery has the potential to transform how we treat and potentially cure once life-threatening diseases.
Manufacturing viral vector-based therapies, such as vaccines and gene and cell therapies, is complex, but a new manufacturing solution helps solve the challenges.
New KUBio box For Viral Vectors Accelerates Gene Therapy Manufacturing
Our industry is experiencing rapid growth in cell and gene therapies. There are over 700 clinical trials underway and approximately 70% utilize viral vectors. The resulting manufacturing capacity shortage requires practical solutions. KUBio box for viral vectors is a turn-key modular platform that provides rapid access to viral vector manufacturing.
